SBRT plus Abiraterone Acetate and ADT versus Abiraterone Acetate and ADT in Oligometastatic Castrate-Resistant Prostate Cancer (ARTO): Long-Term, Unplanned Overall Survival Analysis of an Open-Label, Randomised, Phase 2 Trial - Beyond the Abstract
The original ARTO study demonstrated improvements in biochemical response, biochemical progression-free survival, and radiographic progression-free survival with the addition of SBRT to abiraterone plus androgen deprivation therapy (ADT). These findings established proof-of-concept that local ablation of limited metastatic disease could augment systemic therapy in oligometastatic mCRPC. The current long-term follow-up extends these observations by reporting a statistically significant overall survival advantage, with a hazard ratio of 0.55 favoring the combined treatment approach after a median follow-up exceeding four years. Median overall survival was 50 months in the control arm and had not yet been reached in the SBRT arm.
This is an important milestone because overall survival remains the most clinically meaningful endpoint in advanced prostate cancer. Numerous studies have demonstrated improvements in progression-free survival following metastasis-directed therapy, yet whether delaying progression ultimately translates into patients living longer has remained uncertain. ARTO provides the first randomized evidence in oligometastatic mCRPC suggesting that it can.
Several aspects strengthen the credibility of these findings. First, the magnitude of benefit is remarkably consistent across biochemical progression-free survival, radiographic progression-free survival, and overall survival, suggesting that the observed effect is biologically coherent rather than isolated to a single endpoint. Second, toxicity remained low, with no meaningful increase in serious adverse events attributable to SBRT. Importantly, local treatment did not compromise delivery of systemic therapy, reinforcing the excellent therapeutic ratio that has become characteristic of modern stereotactic radiotherapy.
The results also complement the recently reported PCS-9 trial, which demonstrated improved radiographic progression-free survival when SBRT was combined with enzalutamide. Although PCS-9 was not powered to detect an overall survival difference, the concordance between the two studies strengthens the argument that metastasis-directed therapy represents a genuine therapeutic strategy rather than merely a means of delaying imaging progression. Together, these randomized phase II trials suggest that upfront eradication of visible metastatic disease during ARPI therapy may alter the natural history of carefully selected oligometastatic CRPC.
Nevertheless, several important caveats deserve emphasis before these findings are incorporated broadly into clinical practice.
Patient selection deserves careful consideration. ARTO enrolled a highly selected population characterized by low-volume, non-visceral metastatic disease, excellent performance status, and no more than three metastatic lesions. Median baseline PSA values were low, reflecting patients with relatively indolent disease biology. Consequently, these findings should not be extrapolated to the broader mCRPC population, particularly those with extensive metastatic burden or rapidly progressive disease.
Despite these limitations, the clinical message is increasingly compelling. The cumulative evidence from STOMP, ORIOLE, EXTEND, PCS-9, and now ARTO consistently supports the concept that oligometastatic prostate cancer represents a biologically distinct state in which carefully delivered local therapy can meaningfully complement systemic treatment. ARTO advances this field by providing the first randomized suggestion that this strategy may ultimately improve survival in oligometastatic mCRPC rather than simply postponing disease progression.
For men with low-volume oligometastatic castration-resistant prostate cancer, these results move metastasis-directed therapy from an attractive experimental strategy toward an evidence-supported component of comprehensive disease management.
ARTO provides an important step toward answering one of the most relevant questions in modern prostate cancer care: can treating metastatic lesions improve not only how long patients remain progression-free, but how long they ultimately live? This long-term analysis suggests that the answer may indeed be yes.
Written by: Giulio Francolini, MD, Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
Read the Abstract